GlassScriptPhysician profile
Everett D Trevor
NPI 1104931179
$9,464.76
in general payments reported to CMS, 2019-2025
17 companies · $827 in 2025
The $827 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,455 · 2020: $885 · 2021: $928 · 2022: $2,215 · 2023: $2,076 · 2024: $1,078 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,229 · Long Term Medical Supply Or Device Loan: $752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,229.02 |
| Long Term Medical Supply Or Device Loan | $752.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $4,404.75 | 2019-2025 | (Ad1) Nasal Masks - Traditional, (Di3) Pillow Masks - Over The Head, (Di2) Nasal Masks - Over The Head |
| Fisher & Paykel Healthcare INC | $1,600.29 | 2019-2025 | Fisher & Paykel Healthcare |
| Glaxosmithkline, LLC. | $1,365.51 | 2019-2024 | Arexvy, Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $559.69 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Jazz Pharmaceuticals INC. | $411.73 | 2019-2025 | |
| Resmed Corp | $250.68 | 2019-2024 | |
| Axsome Therapeutics, INC. | $153.74 | 2023-2025 | Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.61 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $114.53 | 2023 | Quviviq |
| Inspire Medical Systems, INC. | $114.19 | 2023-2025 | Inspire |
| Harmony Biosciences LLC | $74.39 | 2021-2023 | Wakix |
| Amgen INC. | $72.26 | 2024-2025 | Tezspire |
| Noctrix Health, INC. | $69.67 | 2024 | Nidra |
| Mylan Specialty L.P. | $55.22 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $32.72 | 2025 | Dupixent |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $23.01 | 2025 | Zepbound |
| Advanced Respiratory, INC | $14.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Everett Trevor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.